Skip to main content
    D

    Design Therapeutics Inc (DSGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.92
    -0.55 (-5.25%)

    Market Cap: $670.46M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Design Therapeutics Inc (DSGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Design Therapeutics are Structure Therapeutics Inc. American Depositary Shares (GPCR), 4D Molecular Therapeutics (FDMT) and Theravance Biopharma (TBPH). By market cap, Design Therapeutics ranks 9th of the 13 companies on this page; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest at $1.43B.

    Peer Comparison

    DSGN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Design Therapeutics (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    4D Molecular Therapeutics Inc (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Zevra Therapeutics Inc. (ZVRA)$540.30M11.6x3.7x52.8%N/A44.9%0.00%
    Taysha Gene Therapies Inc (TSHA)$1.34BN/A300.6x0.0%-32.8%171.3%0.00%
    Solid Biosciences LLC (SLDB)$763.42MN/AN/A0.0%N/A-100.0%0.00%
    Syndax Pharmaceuticals Inc (SNDX)$850.77MN/A2.8x-72.3%-65.0%81.6%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Peer median$690.86M53.4x8.3x0.0%-39.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Design Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    4D Molecular Therapeutics Inc (FDMT)
    4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors.
    FDMT competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Zevra Therapeutics Inc. (ZVRA)
    Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions...
    ZVRA competitors
    Taysha Gene Therapies Inc (TSHA)
    Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies...
    TSHA competitors
    Solid Biosciences LLC (SLDB)
    Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States.
    SLDB competitors
    Syndax Pharmaceuticals Inc (SNDX)
    Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
    SNDX competitors
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.

    Frequently Asked Questions About DSGN

    Who are Design Therapeutics' main competitors?

    The companies most similar to Design Therapeutics include Structure Therapeutics Inc. American Depositary Shares (GPCR), 4D Molecular Therapeutics (FDMT), Theravance Biopharma (TBPH), DiaMedica Therapeutics (DMAC) and Tectonic Therapeutic (TECX), listed from the closest match.

    Who is Design Therapeutics' biggest competitor?

    Structure Therapeutics Inc. American Depositary Shares (GPCR) is both the largest of the similar companies at $1.43B and the closest match by business profile, size, sector and industry.

    How does DSGN stock compare with its competitors?

    DSGN's net margin is 0.0% against a peer median of 0.0%.

    Which of Design Therapeutics' competitors pays a higher dividend?

    Design Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Design Therapeutics bigger than its competitors?

    No. Design Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Structure Therapeutics Inc. American Depositary Shares (GPCR) at $1.43B.